Hepatitis B Virus News and Research

RSS
Experts must monitor new antiviral compounds for HCV treatment

Experts must monitor new antiviral compounds for HCV treatment

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Series of new clinical trials confirm range of viable treatment options for HCV patients

Series of new clinical trials confirm range of viable treatment options for HCV patients

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

Lymphocyte-hepatocyte interactions: Hepatitis C virus changes the rules

Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex announces final results from Phase 3 REALIZE study against HCV

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Boceprevir drug can help cure hard-to-treat hepatitis C

Boceprevir drug can help cure hard-to-treat hepatitis C

Three-drug cocktail more effective against hepatitis C virus

Three-drug cocktail more effective against hepatitis C virus

Smoking withdrawal after liver transplantation may protect against neoplasia development

Smoking withdrawal after liver transplantation may protect against neoplasia development

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.